drugset
Drugs / WSK-V101C
last change Dec 2025 re-read 3 minutes ago

WSK-V101C

also known as Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell)

Vaccine

Developed for
COVID-19
Investigated by
WestVac Biopharma Co., Ltd.

Trials 1

today NCT05911048 · Ph 2
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05911048 Dec 2024 → Jun 2025 overdue COVID-19 WestVac Biopharma Co., Ltd. Not yet recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as WSK-V101C ClinicalTrials.gov intervention name — accepted as the source's own label NCT05911048 ↗
Known as Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) “boost with Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)” NCT05911048 ↗
Modality Vaccine “Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell)” NCT05911048 ↗